File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: 48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
  • Basic View
  • Metadata View
  • XML View
Title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
 
AuthorsHui, CK2
Lai, LSW6
Lam, P2
Zhang, HY2
Fung, TT1
Lai, ST3
Wong, WM4
Lo, CM2
Fan, ST2
Leung, N5
Lau, GKK2
 
Issue Date2006
 
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
CitationAlimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.02887.x
 
AbstractBackground/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.
 
ISSN0269-2813
2012 Impact Factor: 4.548
2012 SCImago Journal Rankings: 1.689
 
DOIhttp://dx.doi.org/10.1111/j.1365-2036.2006.02887.x
 
ISI Accession Number IDWOS:000236392800016
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHui, CK
 
dc.contributor.authorLai, LSW
 
dc.contributor.authorLam, P
 
dc.contributor.authorZhang, HY
 
dc.contributor.authorFung, TT
 
dc.contributor.authorLai, ST
 
dc.contributor.authorWong, WM
 
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.contributor.authorLeung, N
 
dc.contributor.authorLau, GKK
 
dc.date.accessioned2010-09-06T08:53:30Z
 
dc.date.available2010-09-06T08:53:30Z
 
dc.date.issued2006
 
dc.description.abstractBackground/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.02887.x
 
dc.identifier.citeulike571350
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1365-2036.2006.02887.x
 
dc.identifier.epage1178
 
dc.identifier.hkuros116846
 
dc.identifier.isiWOS:000236392800016
 
dc.identifier.issn0269-2813
2012 Impact Factor: 4.548
2012 SCImago Journal Rankings: 1.689
 
dc.identifier.issue8
 
dc.identifier.openurl
 
dc.identifier.pmid16611278
 
dc.identifier.scopuseid_2-s2.0-33646860152
 
dc.identifier.spage1171
 
dc.identifier.urihttp://hdl.handle.net/10722/84484
 
dc.identifier.volume23
 
dc.languageeng
 
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.
 
dc.title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Hui, CK</contributor.author>
<contributor.author>Lai, LSW</contributor.author>
<contributor.author>Lam, P</contributor.author>
<contributor.author>Zhang, HY</contributor.author>
<contributor.author>Fung, TT</contributor.author>
<contributor.author>Lai, ST</contributor.author>
<contributor.author>Wong, WM</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<contributor.author>Leung, N</contributor.author>
<contributor.author>Lau, GKK</contributor.author>
<date.accessioned>2010-09-06T08:53:30Z</date.accessioned>
<date.available>2010-09-06T08:53:30Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>Alimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178</identifier.citation>
<identifier.issn>0269-2813</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/84484</identifier.uri>
<description.abstract>Background/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA &lt;105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA &lt;105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. &#169; 2006 Blackwell Publishing Ltd.</description.abstract>
<language>eng</language>
<publisher>Blackwell Publishing Ltd. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/APT</publisher>
<relation.ispartof>Alimentary Pharmacology and Therapeutics</relation.ispartof>
<rights>Alimentary Pharmacology and Therapeutics. Copyright &#169; Blackwell Publishing Ltd.</rights>
<title>48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0269-2813&amp;volume=23&amp;issue=8&amp;spage=1171&amp;epage=1178&amp;date=2006&amp;atitle=48+weeks+pegylated+interferon+alpha-2a+is+superior+to+24+weeks+of+pegylated+interferon+alpha-2b+in+achieving+hepatitis+B+e+antigen+seroconversion+in+chronic+hepatitis+B+infection</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1111/j.1365-2036.2006.02887.x</identifier.doi>
<identifier.pmid>16611278</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33646860152</identifier.scopus>
<identifier.hkuros>116846</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33646860152&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>23</identifier.volume>
<identifier.issue>8</identifier.issue>
<identifier.spage>1171</identifier.spage>
<identifier.epage>1178</identifier.epage>
<identifier.isi>WOS:000236392800016</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>571350</identifier.citeulike>
</item>
Author Affiliations
  1. Kwong Wah Hospital
  2. The University of Hong Kong
  3. Princess Margaret Hospital Hong Kong
  4. St. Paul's Hospital Hong Kong
  5. Alice Ho Miu Ling Nethersole Hospital
  6. Caritas Medical Centre Hong Kong